Elizabeth Yeu, MD.

NEWARK, Del.—Ace Vision Group, a privately held U.S. ophthalmic medical device company developing Laser Microporation Therapeutic technologies to treat diseases of the aging eye, has appointed Elizabeth Yeu, MD, partner at Virginia Eye Consultants, to the role of chief strategic advisor. In her new position, Yeu will manage AVG's clinical advancement strategy. As an accomplished and well-respected surgeon, researcher, and educator, Yeu has contributed greatly to the field of ophthalmology throughout her more than 20-year career.

Yeu is an avid proponent of novel technologies and disruptive therapeutics that improve the current standard of care for patients. She is recognized and sought after as an industry leader in clinical care and new product development in the ophthalmic surgical and therapeutics spaces.

"I am excited to begin working with AVG in this capacity. I have closely followed the ongoing development of the Laser Scleral Microporation (LSM) technology which began with restoring the loss of dynamic range of focus (DRoF) related to the manifestation of presbyopia," said Dr. Yeu. "I have been impressed by the detailed science behind the VisioLite technology and the clinical results of the multiple LSM studies.

 
The sustainability of the results of each, as well as the consistent reproducible clinical results seen from patient to patient are noteworthy. I am looking forward to serving in this role with AnnMarie Hipsley, DPT, Ph. and the AVG executive management team," said Dr. Yeu.

LSM technology is a minimally invasive rejuvenation procedure for the treatment of presbyopia, glaucoma, and other eye diseases. Currently, AVG is preparing for the commercialization of its VisioLite ophthalmic laser system, an innovative, first-in-class touchless laser technology offering.

In addition to her clinical practice at Virginia Eye Consultants, Dr. Yeu serves on the board of directors for STAAR Surgical, Avellino Lab USA, OSRX Pharmaceuticals and the Virginia Eye Foundation. She also serves as chief medical advisor for Tarsus Pharmaceuticals and executive board member of CVP Physicians, Mid-Atlantic.